Historical Valuation
HENGRUI PHARMA (01276) is now in the Fair zone, suggesting that its current forward PE ratio of 44.94 is considered Fairly compared with the five-year average of 52.82. The fair price of HENGRUI PHARMA (01276) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：78.00
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
HENGRUI PHARMA (01276) has a current Price-to-Book (P/B) ratio of 7.46. Compared to its 3-year average P/B ratio of 7.10 , the current P/B ratio is approximately 4.97% higher. Relative to its 5-year average P/B ratio of 8.03, the current P/B ratio is about -7.10% higher. HENGRUI PHARMA (01276) has a Forward Free Cash Flow (FCF) yield of approximately 2.47%. Compared to its 3-year average FCF yield of 1.43%, the current FCF yield is approximately 73.03% lower. Relative to its 5-year average FCF yield of 1.06% , the current FCF yield is about 132.64% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 01276 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01276 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 01276 currently overvalued or undervalued?
HENGRUI PHARMA (01276) is now in the Fair zone, suggesting that its current forward PE ratio of 44.94 is considered Fairly compared with the five-year average of 52.82. The fair price of HENGRUI PHARMA (01276) is between to according to relative valuation methord.
What is HENGRUI PHARMA (01276) fair value?
01276's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of HENGRUI PHARMA (01276) is between to according to relative valuation methord.
How does 01276's valuation metrics compare to the industry average?
The average P/S ratio for 01276's competitors is , providing a benchmark for relative valuation. HENGRUI PHARMA Corp (01276) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for HENGRUI PHARMA (01276) as of Jan 15 2026?
As of Jan 15 2026, HENGRUI PHARMA (01276) has a P/B ratio of 7.46. This indicates that the market values 01276 at 7.46 times its book value.
What is the current FCF Yield for HENGRUI PHARMA (01276) as of Jan 15 2026?
As of Jan 15 2026, HENGRUI PHARMA (01276) has a FCF Yield of 2.47%. This means that for every dollar of HENGRUI PHARMA’s market capitalization, the company generates 2.47 cents in free cash flow.
What is the current Forward P/E ratio for HENGRUI PHARMA (01276) as of Jan 15 2026?
As of Jan 15 2026, HENGRUI PHARMA (01276) has a Forward P/E ratio of 44.94. This means the market is willing to pay $44.94 for every dollar of HENGRUI PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for HENGRUI PHARMA (01276) as of Jan 15 2026?
As of Jan 15 2026, HENGRUI PHARMA (01276) has a Forward P/S ratio of 11.02. This means the market is valuing 01276 at $11.02 for every dollar of expected revenue over the next 12 months.